NASDAQ:IMRX Immuneering (IMRX) Stock Price, News & Analysis $1.09 -0.04 (-3.54%) (As of 07/5/2024 08:52 PM ET) Add Compare Share Share Today's Range$1.06▼$1.1350-Day Range$1.09▼$1.6952-Week Range$1.05▼$11.06Volume143,000 shsAverage Volume467,637 shsMarket Capitalization$32.32 millionP/E RatioN/ADividend YieldN/APrice Target$13.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Immuneering alerts: Email Address Immuneering MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside1,138.5% Upside$13.50 Price TargetShort InterestBearish17.56% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.45Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.93) to ($2.01) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.74 out of 5 starsMedical Sector598th out of 879 stocksPharmaceutical Preparations Industry281st out of 417 stocks 3.3 Analyst's Opinion Consensus RatingImmuneering has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 4 buy ratings, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageImmuneering has only been the subject of 1 research reports in the past 90 days.Read more about Immuneering's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted17.56% of the float of Immuneering has been sold short.Short Interest Ratio / Days to CoverImmuneering has a short interest ratio ("days to cover") of 9.8.Change versus previous monthShort interest in Immuneering has recently increased by 6.34%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldImmuneering does not currently pay a dividend.Dividend GrowthImmuneering does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IMRX. Previous Next 1.9 News and Social Media Coverage News SentimentImmuneering has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Immuneering this week, compared to 2 articles on an average week.Search Interest1 people have searched for IMRX on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added Immuneering to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Immuneering insiders have not sold or bought any company stock.Percentage Held by Insiders25.00% of the stock of Immuneering is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions67.65% of the stock of Immuneering is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Immuneering's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Immuneering are expected to decrease in the coming year, from ($1.93) to ($2.01) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Immuneering is -0.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Immuneering is -0.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImmuneering has a P/B Ratio of 0.35. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Immuneering's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Awesomely, LLCAutomatic Income (from home)Everyone’s talking about this new income hack that could generate triple digit returns on your money. But here’s the best part…Watch this short video About Immuneering Stock (NASDAQ:IMRX)Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.Read More IMRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IMRX Stock News HeadlinesJuly 4, 2024 | americanbankingnews.comImmuneering Co. (NASDAQ:IMRX) Short Interest UpdateMay 29, 2024 | globenewswire.comImmuneering to Present at the Jefferies Global Healthcare ConferenceJuly 8, 2024 | Crypto 101 Media (Ad)[Urgent] Hedge Funds Expect Major Crypto MovesIn the year following Bitcoin’s last Halving event, that happened in May of 2020… Bitcoin shot up over 550%. But that’s not all… May 19, 2024 | morningstar.comImmuneering Corp Class A IMRXMay 17, 2024 | finanznachrichten.deUSA News Group: Early Detection Breakthrough: Biotech Companies Lead the Way in Pancreatic Cancer TreatmentMay 16, 2024 | markets.businessinsider.comBuy Rating Affirmed for Immuneering with $8 Price Target Amidst Promising Pipeline and Upcoming Data EventsMay 8, 2024 | markets.businessinsider.comBuy Rating Maintained for Immuneering Amid Promising Clinical Pipeline DevelopmentsMay 7, 2024 | globenewswire.comImmuneering Reports First Quarter 2024 Financial Results and Provides Business UpdatesJuly 8, 2024 | Crypto 101 Media (Ad)[Urgent] Hedge Funds Expect Major Crypto MovesIn the year following Bitcoin’s last Halving event, that happened in May of 2020… Bitcoin shot up over 550%. But that’s not all… May 7, 2024 | finance.yahoo.comWe Think Immuneering (NASDAQ:IMRX) Needs To Drive Business Growth CarefullyMay 6, 2024 | globenewswire.comImmuneering Recognizes Melanoma Awareness MonthMay 2, 2024 | markets.businessinsider.comBuy Rating Affirmed: Immuneering’s Lead Asset IMM-1-104 Shows Promise Despite Market SkepticismApril 17, 2024 | msn.comImmuneering (IMRX) Price Target Decreased by 11.43% to 13.55April 11, 2024 | investing.comImmuneering advances pancreatic cancer treatment trialApril 9, 2024 | finanznachrichten.deImmuneering Corporation: IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer ModelsApril 9, 2024 | globenewswire.comIMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer ModelsApril 3, 2024 | globenewswire.comImmuneering to Participate in the 23rd Annual Needham Virtual Healthcare ConferenceMarch 29, 2024 | markets.businessinsider.comBuy Rating Affirmed for Immuneering on Solid Trial Progress and Insider ConfidenceSee More Headlines Receive IMRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immuneering and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/07/2024Today7/08/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:IMRX CUSIPN/A CIK1790340 Webwww.immuneering.com Phone617-500-8080FaxN/AEmployees65Year FoundedN/APrice Target and Rating Average Stock Price Target$13.50 High Stock Price Target$25.00 Low Stock Price Target$3.00 Potential Upside/Downside+1,138.5%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($1.87) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-53,470,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-55.79% Return on Assets-50.47% Debt Debt-to-Equity RatioN/A Current Ratio14.38 Quick Ratio14.38 Sales & Book Value Annual Sales$320,000.00 Price / Sales101.01 Cash FlowN/A Price / Cash FlowN/A Book Value$3.09 per share Price / Book0.35Miscellaneous Outstanding Shares29,653,000Free Float22,240,000Market Cap$32.32 million OptionableNot Optionable Beta-0.61 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for July 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Benjamin J. Zeskind M.B.A. (Age 41)Ph.D., Co-Founder, President, CEO & Director Comp: $935.09kMr. Robert J. Carpenter M.B.A. (Age 78)M.S., Co-Founder & Chair Emeritus Comp: $75.36kDr. Brett M. Hall Ph.D. (Age 55)Chief Scientific Officer Comp: $905.41kMr. Harold E. Brakewood (Age 58)Chief Business Officer Comp: $579.77kMs. Mallory Morales CPA (Age 40)Principal Financial & Accounting Officer, Chief Accounting Officer and Treasurer Ms. Paula George CPADirector of Accounting & Operations and Assistant Corporate ControllerMr. Michael D. Bookman J.D. (Age 37)Chief Legal Officer & Secretary Ms. Leah R. Neufeld (Age 51)Chief People Officer Dr. Peter King Ph.D.Head of Discovery & VPDr. Praveen Nair Ph.D.Head of Translational Pharmacology & VPMore ExecutivesKey CompetitorsRapid Micro BiosystemsNASDAQ:RPIDG1 TherapeuticsNASDAQ:GTHXI-MabNASDAQ:IMABTelomir PharmaceuticalsNASDAQ:TELONuvectis PharmaNASDAQ:NVCTView All CompetitorsInsiders & InstitutionsPrice T Rowe Associates Inc. MDSold 2,467,834 shares on 5/15/2024Ownership: 3.070%Vanguard Group Inc.Bought 129,851 shares on 5/10/2024Ownership: 4.060%Cormorant Asset Management, LpSold 400,000 sharesTotal: $1.16 M ($2.90/share)Peter FeinbergBought 25,000 shares on 3/22/2024Total: $63,750.00 ($2.55/share)Harold Eugene BrakewoodBought 3,900 shares on 3/22/2024Total: $10,023.00 ($2.57/share)View All Insider TransactionsView All Institutional Transactions IMRX Stock Analysis - Frequently Asked Questions How have IMRX shares performed this year? Immuneering's stock was trading at $7.35 at the start of the year. Since then, IMRX shares have decreased by 85.2% and is now trading at $1.09. View the best growth stocks for 2024 here. How were Immuneering's earnings last quarter? Immuneering Co. (NASDAQ:IMRX) issued its quarterly earnings data on Tuesday, May, 7th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.45) by $0.04. When did Immuneering IPO? Immuneering (IMRX) raised $105 million in an initial public offering (IPO) on Friday, July 30th 2021. The company issued 7,000,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, Jefferies, Cowen and Guggenheim Securities served as the underwriters for the IPO. How do I buy shares of Immuneering? Shares of IMRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:IMRX) was last updated on 7/8/2024 by MarketBeat.com Staff From Our PartnersWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredOperation Replace Biden is a GoLast night’s debate proved me right: Joe Biden will be replaced. I’ve been making this warning for months… ...The Freeport Society | SponsoredObama wins Presidential debate When I said Obama would seek a third term… They called me a conspiracy theorist, they said it couldn’t happ...Porter & Company | Sponsored270x more lucrative than NVIDIA???If you've missed out on NVIDIA's recent 1,600% run... Don't worry. Because there's one AI stock that cou...Behind the Markets | SponsoredObama’s DNC coupAs we approach the Democratic National Convention in August... many sense a Biden swap-out is looming. In f...Stansberry Research | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredWho are Nvidia’s New Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immuneering Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immuneering With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.